Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Nanoform Finland Oyj And 2 Other Promising European Penny Stocks

In This Article:

European markets have recently faced challenges, with the pan-European STOXX Europe 600 Index ending about 1.4% lower following new U.S. trade tariffs, which dampened earlier optimism from positive economic updates and geopolitical news. Despite these broader market pressures, investors continue to explore opportunities in various segments, including penny stocks—an area that remains intriguing for those seeking potential growth outside of traditional large-cap investments. Although the term 'penny stocks' might seem outdated, it still captures a segment of smaller or newer companies that can offer affordability and growth potential when supported by solid financials.

Top 10 Penny Stocks In Europe

Name

Share Price

Market Cap

Financial Health Rating

Bredband2 i Skandinavien (OM:BRE2)

SEK1.98

SEK1.9B

★★★★☆☆

Transferator (NGM:TRAN A)

SEK2.30

SEK217.19M

★★★★★☆

Angler Gaming (NGM:ANGL)

SEK3.80

SEK284.94M

★★★★★★

Hifab Group (OM:HIFA B)

SEK3.94

SEK239.71M

★★★★★★

IMS (WSE:IMS)

PLN3.66

PLN124.05M

★★★★☆☆

Cellularline (BIT:CELL)

€2.50

€52.73M

★★★★☆☆

Netgem (ENXTPA:ALNTG)

€0.98

€32.82M

★★★★★★

High (ENXTPA:HCO)

€3.14

€61.68M

★★★★★★

Fondia Oyj (HLSE:FONDIA)

€4.88

€18.23M

★★★★★★

Deceuninck (ENXTBR:DECB)

€2.18

€300.98M

★★★★★★

Click here to see the full list of 418 stocks from our European Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Nanoform Finland Oyj

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nanoform Finland Oyj provides nanotechnology and drug particle engineering services to the pharma and biotech industries in Europe and the United States, with a market cap of €104.35 million.

Operations: The company's revenue of €3.66 million is generated from its expertise in nanotechnology and drug particle engineering services.

Market Cap: €104.35M

Nanoform Finland Oyj, with a market cap of €104.35 million, operates in the nanotechnology and drug particle engineering sector but remains unprofitable with a net loss of €23.43 million for 2024. Despite its revenue of €2.78 million, it is considered pre-revenue due to limited significant income streams. The company is debt-free and has sufficient cash runway for over three years even if free cash flow continues to decline at historical rates. However, its share price has been highly volatile recently and profitability isn't expected within the next three years despite projected revenue growth of 43.65% annually.